Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
87 hedge funds and large institutions have $57.9M invested in Five Prime Therapeutics, Inc. in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 29 reducing their positions, and 21 closing their positions.
7% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 29
7% less funds holding
Funds holding: 94 → 87 (-7)
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
53% less capital invested
Capital invested by funds: $122M → $57.9M (-$64.4M)
84% less call options, than puts
Call options by funds: $160K | Put options by funds: $1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.09M |
| 2 |
Renaissance Technologies
New York
|
+$891K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$744K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$441K |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$301K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.48M |
| 2 |
JP Morgan Chase
New York
|
-$1.38M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.35M |
| 4 |
Man Group
London,
United Kingdom
|
-$1.33M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$934K |
FPRX Hedge Fund Activity: Q1 2020 in Review
87 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q1 2020, worth a combined $57.9M — down 53% from $122M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of FPRX and 14 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 27 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.09M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $1.48M.
- 87 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q1 2020, down from 94 in Q4 2019.
- Funds reported $57.9M of Five Prime Therapeutics, Inc. stock for Q1 2020, down 53% quarter-over-quarter.
- 14 funds opened new Five Prime Therapeutics, Inc. positions in Q1 2020 and 21 closed out, a net change of -7 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q1 2020 was EcoR1 Capital, an estimated $1.09M added.
- The largest Five Prime Therapeutics, Inc. seller in Q1 2020 was Jacobs Levy Equity Management, an estimated $1.48M sold.
Based on aggregated 13F filings for Q1 2020.